Responses of trabecular and cortical bone turnover and bone mass and strength to bisphosphonate YH529 in ovariohysterectomized beagles with calcium restriction

Journal of Bone and Mineral Research

Volumn 13, Issue 6, 1998, Pages 1011-1022

  Yoshida, Yasushi ^a   Moriya, Atsuko ^a   Kitamura, Kazuyuki ^a   Inazu, Mizuho ^a   Okimoto, Nobukazu ^b   Okazaki, Yuichi ^b   Nakamura, Toshitaka ^b,c  

^a SANOFI   (France)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 HYDROXY 2 IMIDAZOL (1,2 A)PYRIDIN 3 YL ETHYLIDENE BISPHOSPHONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; MINODRONIC ACID; UNCLASSIFIED DRUG;

ALKALINE PHOSPHATASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE REMODELING; BONE STRENGTH; BONE TURNOVER; CALCIUM BLOOD LEVEL; CALCIUM INTAKE; CONTROLLED STUDY; CORTICAL BONE; DOG; DOSE RESPONSE; DRUG EFFECT; FEMALE; HYSTERECTOMY; MORPHOMETRICS; NONHUMAN; ORAL DRUG ADMINISTRATION; OVARIECTOMY; PHOSPHATE BLOOD LEVEL; PROTEIN BLOOD LEVEL; TRABECULAR BONE; URINARY EXCRETION;

ADMINISTRATION, ORAL; ANIMALS; BIOMECHANICS; BONE DENSITY; CALCIUM; CALCIUM, DIETARY; DIPHOSPHONATES; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMUR; HUMANS; HYSTERECTOMY; IMIDAZOLES; LUMBAR VERTEBRAE; OSTEOCALCIN; OSTEOCLASTS; OVARIECTOMY; TIBIA;

EID: 0031800273     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/jbmr.1998.13.6.1011     Document Type: Article

References (39)

1. Parfitt AM, Mathews CHE, Villanueva AR, Kleerekoper M, Frame B, Rao DS 1983 Relationships between surface, volume, and thickness of iliac trabecular bone in aging and in osteoporosis: Implications for the microanatomic and cellular mechanisms of bone loss. J Clin Invest 72:1396-1409.
2. Wronski TJ, Cintron M, Dann LM 1988 Temporal relationship between bone Joss and increased bone turnover in ovariectomized rats. Calcif Tissue Int 43:179-183.
3. Yamaura M, Nakamura T, Tsurukami H, Hijioka A, Narusawa K, Ohnishi H, Ohta T, Hosoda K 1996 Local bone turnover in the metaphysis of the proximal tibia and the lumbar vertebra during the early periods after ovariectomy in rats. Calcif Tissue Int 58:52-59.
4. Faugere MC, Friedler RM, Fanti P, Malluche HH 1990 Bone changes occurring early after cessation of ovarian function in beagle dogs: A histomorphometric study employing sequential biopsies. J Bone Miner Res 5:263-272.
5. Peck WA, Burckhardt P, Christiansen C, Fleisch HA, Genant HK, Gennari C, Martin TJ, Martini L, Morita R, Ogata E, Rapado A, Shulman LE, Stern PH, Young RTT 1993 Diagnosis, Prophylaxis and Treatment of Osteoporosis. Consensus Development Conference. 27 March-2 April, Hong Kong.
6. Fleisch H 1991 Bisphosphonates: Pharmacology and use in the treatment of tumor-induced hyper calcemic and metastatic bone disease. Drugs 42:919-944.
7. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA 1993 The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586.
8. Faugere MCM, Friedler RM, Bauss F, Malluche HH 1993 A new bisphosphonate, BM21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 8:1345-1355.
9. Motoie H, Nakamura T, Ohuchi N, Nishikawa H, Kanoh H, Abe T, Kawashima H 1995 Effects of the bisphosphonate YM175 on bone mineral density, strength, structure, and turnover in ovariectomized beagles on concomitant dietary calcium restriction. J Bone Miner Res 10:910-920.
10. Grynpas MD, Kasra M, Renlund R, Pritzker KP 1995 The effect of pamidronate in a new model of immobilization in the dog. Bone 17 (Suppl 4):225S-232S.
11. Parfitt AM 1988 Bone remodeling: Relationship to the amount and structure of bone, and the pathogenesis and prevention of fractures. In: Riggs BL, Melton LJ III (eds.) Osteoporosis: Etiology, Diagnosis, and Management. Raven Press, New York, NY, pp. 45-99.
12. FDA 1994 Guidelines for Preclinical and Clinical Evaluation of Agents Used in the Prevention or Treatment of Postmenopausal Osteoporosis. Division of Metabolism and Endocrine Drug Pruducts, FDA, Rockville, MD, U.S.A.
13. Kimmel DB 1991 The oophorectomized beagle as an experimental model for estrogen-depletion bone loss in the adult human. Cells Mater (Suppl 1):75-84.
14. 3 corrects bone loss but suppresses bone remodeling in ovariohysterectomized beagle dog. Endocrinology 122:1998-2006.
15. 1896 Guiding principles for research involving animals and human beings. Am J Physiol 250:E110.
16. 3. Bone 10:117-123.
17. Katsumata T, Nakamura T, Ohnishi H, Sakurama T 1995 Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J Bone Miner Res 10:921-931.
18. Mosekilde L, Danielsen CC, Knudsen UB 1993 The effect of aging and ovariectomy on the vertebral bone mass and biomechanical properties of mature rats. Bone 14:1-6.
19. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Malluche H, Meunier PJ, Ott SM, Recker RR 1987 Bone histomorphometry: Standardization of nomenclature, symbols, and units. Report of ASBMR Histomorphometry Committee. J Bone Miner Res 2:595-610.
20. 3 (ED-71), increases bone mass by stimulating the bone formation in normal and ovariectomized rats. Calcif Tissue Int 54:142-149.
21. Westful PH, Young SS 1992 Resampling-Based Multiple Testing. Wiley & Sons, New York, NY, U.S.A.
22. Kimmel DB, Wronski TJ 1990 Non-destructive measurement of bone mineral in femurs from ovariectomized rats. Calcif Tissue Int 46:101-110.
23. Heaney RP 1993 Nutritional factors in osteoporosis. Annu Rev Nutr 13:287-316.
24. Heaney RP 1996 Pathogenesis of postmenopausal osteoporosis. In: Favus MJ (ed.) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 3rd Ed. Lippincott-Raven, Philadelphia, PA, U.S.A., pp. 252-254.
25. Hodgkinson A, Aaron JE, Horsman A, McLachlan MSF, Nordin BEC 1978 Effect of oophorectomy and calcium deprivation on bone mass in rats. Clin Sci Mol Med 54:439-446.
26. Eastell R, Delmas PD, Hodgson SF, Eriksen EF, Mann KG, Riggs BL 1988 Bone formation rate in older normal women: Concurrent assessment with bone histomorphometry, calcium kinetics, and biochemical markers. J Clin Endocrinol Metab 67:741-748.
27. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD 1994 Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700.
28. Yokose S, Ishizuya T, Ikeda T, Nakamura T, Tusrukami H, Kawasaki K, Suda T, Yoshiki S, Yamaguchi A 1996 An estrogen deficiency caused by ovariectomy increases plasma levels of systemic factors that stimulate proliferation and differentiation of osteoblasts in rats. Endocrinology 137:469-478.
29. Ohnishi H, Nakamura T, Narusawa K, Murakami H, Abe M, Barbier A, Suzuki K 1997 Bisphosphonate tiludronate increases bone strength by improving mass and structure in established osteopenia after ovariectomy in rats. Bone 21: 335-343.
30. Toolan BC, Shea M, Myers ER, Borchers RE, Seedor JG, Quartuccio H, Rodan G, Hayes WC 1992 Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J Bone Miner Res 7:1399-1406.
31. Boyce RW, Paddock CL, Gleason JR, Sletsema WK, Eriksen EF 1995 The effects of risedronate on canine cancellous bone remodeling: Three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res 10:211-221.
32. Lafage MH, Balena R, Battle MA, Shea M, Seedor JG, Klein H, Hayes WC, Rodan GA 1995 Comparison of alendronate and sodium fluoride effects on cancellous and cortical bone in minipigs: A one-year study. J Clin Invest 95:2127-2133.
33. Chappard D, Alexandre C, Falle S, Vico L, Morukov BV, Rodionova SS, Minaire P, Riffat G 1989 Effects of a bisphosphonate (1-hydroxyethyldene-1,1-bisphosphonic acid) on osteoclast number during prolonged bed rest in healthy humans. Metabolism 38:822-825.
34. Chappard D, Petitjean M, Alexandre C, Vico L, Minaire P, Riffat G 1991 Cortical osteoclasts are less sensitive to etidronate than trabecular osteoclasts. J Bone Miner Res 6:673-680.
35. Frost HM 1988 Vital biomechanics: Proposed general concepts for skeletal adaptations to mechanical usage. Calcif Tissue Int 42:145-156.
36. Rodan GA 1991 Perspectives: Mechanical loading, estrogen deficiency, and the coupling of bone formation and resorption. J Bone Miner Res 6:527-530.
37. Balena R, Markatos A, Guy J, Shea M, Seedor JG, Hayes WC, Peter CP, Rodan GA 1993 Effects of three year treatment with alendronate in adult beagles. J Bone Miner Res 8:S614 (abstract).
38. Rodan GA 1997 Bone mass homeostasis and bisphosphonate action. Bone 20:1-4.
39. Frost HM 1992 Perspectives: The role of changes in mechanical usage set points in the pathogenesis of osteoporosis. J Bone Miner Res 7:253-261.